Stay updated on Archway Study: PDS vs Monthly Ranibizumab in Wet AMD Clinical Trial

Sign up to get notified when there's something new on the Archway Study: PDS vs Monthly Ranibizumab in Wet AMD Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Archway Study: PDS vs Monthly Ranibizumab in Wet AMD Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the efficacy, safety, and pharmacokinetics evaluation of the Port Delivery System with ranibizumab compared to intravitreal injections in participants with neovascular age-related macular degeneration.
    Difference
    0.1%
    Check dated 2024-06-06T14:50:44.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participants, specifying that researchers are looking for individuals aged 50 years or older with a recent diagnosis of neovascular age-related macular degeneration (nAMD) and a history of specific treatments. Previously, no information was provided under the Participation Criteria Collaborators section.
    Difference
    21%
    Check dated 2024-05-22T21:31:11.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:39:39.000Z thumbnail image

Stay in the know with updates to Archway Study: PDS vs Monthly Ranibizumab in Wet AMD Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Archway Study: PDS vs Monthly Ranibizumab in Wet AMD Clinical Trial page.